Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Nicola Pannacciulli"'
Autor:
Andrew D. Hershey, Gabriel Paiva da Silva Lima, Nicola Pannacciulli, Mia Mackowski, Reija Koukakis, Jennifer Williams McVige
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 3, Pp n/a-n/a (2024)
Abstract Erenumab, a fully human monoclonal antibody targeting the calcitonin gene‐related peptide receptor, is efficacious and safe for prevention of attacks of migraine in adults. This phase I, randomized, open‐label, multiple‐dose study eval
Externí odkaz:
https://doaj.org/article/c293b63db7ac48dbb3a15686ef74069e
Autor:
Ethel Siris, Michele McDermott, Nicola Pannacciulli, Paul D Miller, E Michael Lewiecki, Roland Chapurlat, Esteban Jódar‐Gimeno, Shuang Huang, John A Kanis
Publikováno v:
JBMR Plus, Vol 4, Iss 4, Pp n/a-n/a (2020)
ABSTRACT The 3‐year placebo‐controlled FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the antifracture efficacy of denosumab in postmenopausal women with osteoporosis. The 7‐year open‐lab
Externí odkaz:
https://doaj.org/article/9f0cc4a05fd3401887b10a516bfcbe37
Autor:
Yan Shi, Ying Wang, Wei Meng, Robert P. Brigance, Denis E. Ryono, Scott Bolton, Hao Zhang, Sean Chen, Rebecca Smirk, Shiwei Tao, Joseph A. Tino, Kristin N. Williams, Richard Sulsky, Laura Nielsen, Bruce Ellsworth, Michael K. Y. Wong, Jung-Hui Sun, Leslie W. Leith, Dawn Sun, Dauh-Rurng Wu, Anuradha Gupta, Richard Rampulla, Arvind Mathur, Bang-Chi Chen, Aiying Wang, Helen G. Fuentes-Catanio, Lori Kunselman, Michael Cap, Jacob Zalaznick, Xiaohui Ma, Heng Liu, Joseph R. Taylor, Rachel Zebo, Beverly Jones, Stephen Kalinowski, Joann Swartz, Ada Staal, Kevin O’Malley, Lisa Kopcho, Jodi K. Muckelbauer, Stanley R. Krystek, Steven A. Spronk, Jovita Marcinkeviciene, Gerry Everlof, Xue-Qing Chen, Carrie Xu, Yi-Xin Li, Robert A. Langish, Yanou Yang, Qi Wang, Kamelia Behnia, Aberra Fura, Evan B. Janovitz, Nicola Pannacciulli, Steven Griffen, Bradley A. Zinker, John Krupinski, Mark Kirby, Jean Whaley, Robert Zahler, Joel C. Barrish, Jeffrey A. Robl, Peter T. W. Cheng
Publikováno v:
Journal of Medicinal Chemistry. 65:4291-4317
Autor:
Peter W. Butler, Osvaldo D. Messina, Jonathan D. Adachi, Ronald Emkey, Kenneth G. Saag, J. Morales-Torres, Willem F. Lems, Xiang Yin, Nicola Pannacciulli, Piet Geusens
Publikováno v:
Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis and Rheumatology, 71(7), 1174-1184. John Wiley and Sons Ltd
Arthritis & Rheumatology, 71(7), 1174-1184. Wiley
Saag, K G, Pannacciulli, N, Geusens, P, Adachi, J D, Messina, O D, Morales-Torres, J, Emkey, R, Butler, P W, Yin, X & Lems, W F 2019, ' Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four–Month Randomized, Double-Blind, Double-Dummy Trial ', Arthritis and Rheumatology, vol. 71, no. 7, pp. 1174-1184 . https://doi.org/10.1002/art.40874
Arthritis and Rheumatology, 71(7), 1174-1184. John Wiley and Sons Ltd
Arthritis & Rheumatology, 71(7), 1174-1184. Wiley
Saag, K G, Pannacciulli, N, Geusens, P, Adachi, J D, Messina, O D, Morales-Torres, J, Emkey, R, Butler, P W, Yin, X & Lems, W F 2019, ' Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four–Month Randomized, Double-Blind, Double-Dummy Trial ', Arthritis and Rheumatology, vol. 71, no. 7, pp. 1174-1184 . https://doi.org/10.1002/art.40874
Objective: Clinical trial results have shown that, in glucocorticoid-treated patients, treatment with denosumab 60 mg subcutaneously once every 6 months (Q6M) increased spine and hip bone mineral density (BMD) at month 12 significantly more than trea
Autor:
C. Wang, Jacques P. Brown, Shuang Huang, Paul D. Miller, Willem F. Lems, Arkadi Chines, A. Singer, Edward Czerwiński, Henry G. Bone, Nicola Pannacciulli, J. Malouf-Sierra
Publikováno v:
Miller, P D, Pannacciulli, N, Malouf-Sierra, J, Singer, A, Czerwiński, E, Bone, H G, Wang, C, Huang, S, Chines, A, Lems, W & Brown, J P 2020, ' Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates ', Osteoporosis International, vol. 31, no. 1, pp. 181-191 . https://doi.org/10.1007/s00198-019-05233-x
OSTEOPOROSIS INTERNATIONAL
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Osteoporosis International, 31(1), 181-191. Springer London
OSTEOPOROSIS INTERNATIONAL
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Osteoporosis International, 31(1), 181-191. Springer London
Summary: Transitioning postmenopausal women with osteoporosis from a bisphosphonate to denosumab appears to be safe and more effective at improving BMD than continuing treatment with a bisphosphonate. Introduction: We conducted a patient-level pooled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35744420405ff1b63b3c1f5ce7053b92
https://research.vumc.nl/en/publications/69264bc8-b6ff-4e7a-8ec8-51c206123993
https://research.vumc.nl/en/publications/69264bc8-b6ff-4e7a-8ec8-51c206123993
Autor:
Esteban Jódar-Gimeno, Nicola Pannacciulli, John A. Kanis, Ethel S. Siris, Michele McDermott, Roland Chapurlat, E. Michael Lewiecki, Shuang Huang, Paul D. Miller
Publikováno v:
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
JBMR Plus, Vol 4, Iss 4, Pp n/a-n/a (2020)
JBMR Plus
Universidad Europea (UEM)
JBMR Plus, Vol 4, Iss 4, Pp n/a-n/a (2020)
JBMR Plus
The 3-year placebo-controlled FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the antifracture efficacy of denosumab in postmenopausal women with osteoporosis. The 7-year open-label extension demo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df3cde717d589d3f063981fb07bb7b87
https://hdl.handle.net/11268/10657
https://hdl.handle.net/11268/10657
Autor:
Robert A. Adler, Jeffrey R. Curtis, Akhila Balasubramanian, Nicola Pannacciulli, Kenneth G. Saag, Sally W. Wade
Publikováno v:
Journal of Bone and Mineral Research. 33:1881-1888
The purpose of this work was to evaluate systemic glucocorticoid exposure and fracture among patients with newly-diagnosed inflammatory and immune-modulated conditions. Using administrative data, inception cohorts of rheumatoid arthritis (RA), asthma
Autor:
Neil Binkley, Nicola Napoli, Ethel S. Siris, E. Michael Lewiecki, Nicola Pannacciulli, Shuang Huang, Peter W. Butler, Daria B. Crittenden, Serge Ferrari, David L. Kendler
Publikováno v:
Bone, Vol. 134 (2020) P. 115287
Antiresorptive therapies reduce fracture risk; however, long-term bone turnover inhibition may raise concerns about rare, but serious, skeletal adverse events—atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ). Denosumab, a fully hu
Autor:
Kenneth G. Saag, Andrea Wang, Piet Geusens, Rachel B. Wagman, Osvaldo D. Messina, Nicola Pannacciulli, Willem F. Lems, Ronald Emkey, Jonathan D. Adachi, Roland Chapurlat
Publikováno v:
The Lancet Diabetes & Endocrinology, 6(6), 445-454. Elsevier Science
Background Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and is associated with an estimated annual fracture rate of 5%. We aimed to assess the efficacy and safety of denosumab compared with risedronate in gluc
Autor:
Nancy E Lane, Eric Lespessailles, Stefan Goemaere, Joop P. W. van den Bergh, Xiang Yin, Roland Chapurlat, Nicola Pannacciulli, Rachel B. Wagman, Osvaldo D. Messina, Piet Geusens
Publikováno v:
Oral Presentations.
Background In a study of patients initiating or continuing GC, 12 and 24 months gains in lumbar spine and total hip areal bone mineral density (aBMD) were greater with DMAb vs RIS.1,2 Objectives Evaluate the effects of DMAb vs RIS on cortical and tra